Purpose: We tested whether the combination of 4 established cell cycle regulators (p53, pRB, p21 and p27) could improve the ability to predict clinical outcomes in a large multi-institutional collaboration of patients with pT3-4N0 or pTany Npositive urothelial carcinoma of the bladder. We also assessed whether the combination of molecular markers is superior to any individual biomarker. Materials and Methods: The study comprised 692 patients with pT3-4N0 or pTany Npositive urothelial carcinoma of the bladder treated with radical cystectomy and bilateral lymphadenectomy (median followup 5.3 years). Scoring was performed using advanced cell imaging and color detection software. The base model incorporated patient age, gender, stage, grade, ly...
Bladder cancer is a common type of cancer, especially among men in developed countries. Most cancers...
The search for molecular markers that will permit the opti-mized individual management of patients w...
Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Ea...
Purpose: We tested whether the combination of 4 established cell cycle regulators (p53, pRB, p21 and...
OBJECTIVE: The aim of the study was to confirm the predictive value of cell cycle regulatory protein...
Abstract: Bladder cancer is the fourth most common malignancy in the US and is associated with the h...
Bladder cancer (BC) is a heterogeneous disease encompassing distinct biologic features that lead to ...
Contains fulltext : 47399schalken.pdf (publisher's version ) (Closed access)The In...
OBJECTIVES: To summarize the current status of clinicopathological and molecular markers for the pre...
Contains fulltext : 79653.pdf (publisher's version ) (Closed access)Many markers f...
Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast hetero...
Detailed molecular insights into bladder cancer biology might allow more detailed prognostication an...
Objective: To identify candidate biomarkers correlated with clinical prognosis of patients with blad...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
Bladder cancer is a common type of cancer, especially among men in developed countries. Most cancers...
The search for molecular markers that will permit the opti-mized individual management of patients w...
Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Ea...
Purpose: We tested whether the combination of 4 established cell cycle regulators (p53, pRB, p21 and...
OBJECTIVE: The aim of the study was to confirm the predictive value of cell cycle regulatory protein...
Abstract: Bladder cancer is the fourth most common malignancy in the US and is associated with the h...
Bladder cancer (BC) is a heterogeneous disease encompassing distinct biologic features that lead to ...
Contains fulltext : 47399schalken.pdf (publisher's version ) (Closed access)The In...
OBJECTIVES: To summarize the current status of clinicopathological and molecular markers for the pre...
Contains fulltext : 79653.pdf (publisher's version ) (Closed access)Many markers f...
Bladder cancer is associated with high recurrence and mortality rates. These tumors show vast hetero...
Detailed molecular insights into bladder cancer biology might allow more detailed prognostication an...
Objective: To identify candidate biomarkers correlated with clinical prognosis of patients with blad...
Bladder cancer (BC) is one of the most expensive lifetime cancers to treat because of the high recur...
UnrestrictedUrothelial carcinoma of the urinary bladder is the seventh most common type of cancer wo...
Bladder cancer is a common type of cancer, especially among men in developed countries. Most cancers...
The search for molecular markers that will permit the opti-mized individual management of patients w...
Bladder cancer tumors can be divided into two molecular subtypes referred to as luminal or basal. Ea...